12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

MoxDuo IR morphine/oxycodone regulatory update

FDA accepted for review a resubmitted NDA from QRxPharma for MoxDuo IR morphine/oxycodone to treat moderate to severe acute pain. The PDUFA date is May 25, with a launch planned for 2H14, if approved. QRxPharma said FDA will schedule an advisory committee meeting to discuss...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >